Giapreza

mergers acquisitions

Pharma

Struggling La Jolla sells out to Innoviva for $149M

With sales of blood pressure medicine Giapreza lagging, La Jolla has sold out to royalty management company Innoviva for $149 million.

Kevin Dunleavy Jul 11, 2022 10:37am

drug names bracket FPMK

#FierceMadness: Brineura, Kymriah come up big

Mar 19, 2018 11:30am

fda

With La Jolla's Giapreza nod, FDA hits 46 for the year

Dec 22, 2017 9:50am